FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095804947> ?p ?o ?g. }

• W2095804947 endingPage "798" @default.
• W2095804947 startingPage "797" @default.
• W2095804947 abstract "Interstitial lung disease (ILD) is a potentially fatal complication of the idiopathic inflammatory myopathies occurring in 5% to 40% of patients with classic dermatomyositis (DM).1Hirakata M Nagai S Interstitial lung disease in polymyositis and dermatomyositis.Curr Opin Rheumatol. 2000; 12: 501-508Crossref PubMed Scopus (125) Google Scholar, 2Douglas WW Tazelaar HD Hartman TE Hartman RP Decker PA Schroeder DR et al.Polymyositis-dermatomyositis-associated interstitial lung disease.Am J Respir Crit Care Med. 2001; 164: 1182-1185Crossref PubMed Scopus (469) Google Scholar However, it is not generally appreciated that ILD can also occur in subsets of DM that lack hallmark clinical features such as muscle weakness (eg, clinically amyopathic DM [C-ADM]). C-ADM (synonym, DM siné myositis) is a subset of idiopathic inflammatory myopathies in which the hallmark cutaneous manifestations of DM (ie, DM-specific skin disease [DMSSD]) are present for 6 months or longer without the development of clinically evident muscle weakness.3Sontheimer RD Cutaneous features of classical dermatomyositis and amyopathic dermatomyositis.Curr Opin Rheumatol. 1999; 11: 475-482Crossref PubMed Scopus (161) Google Scholar, 4Sontheimer RD Would a new name hasten the acceptance of clinically amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.J Am Acad Dermatol. 2002; 46: 626-636Abstract Full Text Full Text PDF PubMed Scopus (357) Google Scholar, 5Caproni M Cardinali C Parodi A Giomi B Papini M Vaccaro M et al.Amyopathic dermatomyositis: a review by the Italian group of immunodermatology.Arch Dermatol. 2002; 138: 23-27Crossref PubMed Google Scholar Although previously thought to be quite rare, more than 300 cases of C-ADM have now been published. Among these cases, we were surprised to find 34 published cases of often fatal ILD occurring in patients having DMSSD but no muscle weakness (Table I). Many of these reports have been published in languages other than English, especially Japanese. Not all of these cases meet the classification criteria for C-ADM because DMSSD in some cases had been present for less than 6 months when ILD presented clinically. However, these cases were included in the present analysis because they do represent ILD occurring in the context of DMSSD without the presence of muscle weakness.Table ISummary of published cases of interstitial lung disease occurring in patients with dermatomyositis-specific skin disease but no muscle weaknessClinical featuresAll cases (N = 34)Japanese cases (n = 27)Other cases (n = 7)Mean age, y (range)53.4 (10-88)54.5 (23-84)49.0 (10-88)Median age, y525247Male/female ratio14:2011:163:4C-ADM subclassification†ADM-14; HDM-4ADM-11; HDM-3ADM-3; HDM-1Mean interval (y) between onset of DMSSD and diagnosis of ILD (range)1.49 (0.08-18.0)1.06 (0.12-4.0)3.42 (0.08-18.0)Median interval (y) between onset of DMSSD and diagnosis of ILD0.830.830.65Fatal outcome from ILD (%)18/34 (53)16/27 (59)2/7 (29)Antinuclear antibody (%)6/27‡(22)5/22 (23)1/5 (20)Myositis-specific antibodies (Jo-1)0/260/230/3ESR mean value, mm/h44 (24 tested)52 (19 tested)35 (5 tested)Associated malignancy (%)1/34 (3)1/27 (4)0/7*Countries from which non-Japanese cases were reported: Australia (1), Brazil (1), Malaysia (1), Korea (1), United States (1), West Indes (1), Yugoslavia (1). †C-ADM can be subclassified as follows: ADM (DMSSD for at least 6 months or longer without muscle weakness, normal muscle enzymes, and no other laboratory or radiologic evidence of muscle inflammation [eg, electromyography, muscle biopsy, muscle spectroscopy]); HDM (DMSSD for at least 6 months or longer without muscle weakness, normal muscle enzymes but some degree of other clinically silent laboratory or radiologic evidence of myositis). The key distinguishing feature of C-ADM is the fact that such patients display DMSSD for atypically prolonged periods of time without accompanying muscle weakness that is typical of classical DM. (Not all patients included in this analysis could be subclassified as either ADM or HDM since some had DMSSD for less than 6 months at the time of onset of their ILD.) ‡Number positive or abnormal/number tested.ADM, Amyopathic dermatomyositis (DM); C-, clinically; DMSSD, DM-specific skin disease; ESR, erythrocyte sedimentation rate; HDM, hypomyopathic DM; ILD, interstitial lung disease. Open table in a new tab ADM, Amyopathic dermatomyositis (DM); C-, clinically; DMSSD, DM-specific skin disease; ESR, erythrocyte sedimentation rate; HDM, hypomyopathic DM; ILD, interstitial lung disease. In addition to the 34 published cases summarized in Table I, we are aware of several other such cases reported in abstract form (5 cases), on Internet Web sites (2 cases, both fatal), and by personal communication (1 case, fatal). Thus, there can be little doubt that clinical evidence of muscle weakness need not be present for the development of potentially fatal, DM-associated ILD. Failure to recognize this clinical constellation can delay diagnosis and institution of proper treatment and, thereby, have disastrous NO LABELPublished online March 11, 2003" @default.
• W2095804947 created "2016-06-24" @default.
• W2095804947 creator A5014463694 @default.
• W2095804947 creator A5026655166 @default.
• W2095804947 date "2003-05-01" @default.
• W2095804947 modified "2023-10-18" @default.
• W2095804947 title "Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis" @default.
• W2095804947 cites W1972401899 @default.
• W2095804947 cites W2074738166 @default.
• W2095804947 cites W2088338885 @default.
• W2095804947 cites W2115404234 @default.
• W2095804947 cites W2158310356 @default.
• W2095804947 doi "https://doi.org/10.1067/mjd.2003.199" @default.
• W2095804947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12734516" @default.
• W2095804947 hasPublicationYear "2003" @default.
• W2095804947 type Work @default.
• W2095804947 sameAs 2095804947 @default.
• W2095804947 citedByCount "50" @default.
• W2095804947 countsByYear W20958049472012 @default.
• W2095804947 countsByYear W20958049472013 @default.
• W2095804947 countsByYear W20958049472014 @default.
• W2095804947 countsByYear W20958049472015 @default.
• W2095804947 countsByYear W20958049472016 @default.
• W2095804947 countsByYear W20958049472017 @default.
• W2095804947 countsByYear W20958049472018 @default.
• W2095804947 countsByYear W20958049472019 @default.
• W2095804947 countsByYear W20958049472023 @default.
• W2095804947 crossrefType "journal-article" @default.
• W2095804947 hasAuthorship W2095804947A5014463694 @default.
• W2095804947 hasAuthorship W2095804947A5026655166 @default.
• W2095804947 hasBestOaLocation W20958049471 @default.
• W2095804947 hasConcept C126322002 @default.
• W2095804947 hasConcept C142724271 @default.
• W2095804947 hasConcept C16005928 @default.
• W2095804947 hasConcept C2775934546 @default.
• W2095804947 hasConcept C2776418732 @default.
• W2095804947 hasConcept C2777543607 @default.
• W2095804947 hasConcept C2777714996 @default.
• W2095804947 hasConcept C2778751314 @default.
• W2095804947 hasConcept C2779387793 @default.
• W2095804947 hasConcept C2779999465 @default.
• W2095804947 hasConcept C2781232998 @default.
• W2095804947 hasConcept C2909745897 @default.
• W2095804947 hasConcept C71924100 @default.
• W2095804947 hasConceptScore W2095804947C126322002 @default.
• W2095804947 hasConceptScore W2095804947C142724271 @default.
• W2095804947 hasConceptScore W2095804947C16005928 @default.
• W2095804947 hasConceptScore W2095804947C2775934546 @default.
• W2095804947 hasConceptScore W2095804947C2776418732 @default.
• W2095804947 hasConceptScore W2095804947C2777543607 @default.
• W2095804947 hasConceptScore W2095804947C2777714996 @default.
• W2095804947 hasConceptScore W2095804947C2778751314 @default.
• W2095804947 hasConceptScore W2095804947C2779387793 @default.
• W2095804947 hasConceptScore W2095804947C2779999465 @default.
• W2095804947 hasConceptScore W2095804947C2781232998 @default.
• W2095804947 hasConceptScore W2095804947C2909745897 @default.
• W2095804947 hasConceptScore W2095804947C71924100 @default.
• W2095804947 hasIssue "5" @default.
• W2095804947 hasLocation W20958049471 @default.
• W2095804947 hasLocation W20958049472 @default.
• W2095804947 hasOpenAccess W2095804947 @default.
• W2095804947 hasPrimaryLocation W20958049471 @default.
• W2095804947 hasRelatedWork W1848853854 @default.
• W2095804947 hasRelatedWork W2030362303 @default.
• W2095804947 hasRelatedWork W2057134454 @default.
• W2095804947 hasRelatedWork W2095804947 @default.
• W2095804947 hasRelatedWork W2152218879 @default.
• W2095804947 hasRelatedWork W2165122376 @default.
• W2095804947 hasRelatedWork W2416152610 @default.
• W2095804947 hasRelatedWork W2790041041 @default.
• W2095804947 hasRelatedWork W3119342182 @default.
• W2095804947 hasRelatedWork W4321440362 @default.
• W2095804947 hasVolume "48" @default.
• W2095804947 isParatext "false" @default.
• W2095804947 isRetracted "false" @default.
• W2095804947 magId "2095804947" @default.
• W2095804947 workType "article" @default.